Healthy Skepticism Library item: 6740

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

MaLAM complaints to the APMA
MaLAM Australian News 1997 May-Jun; 5:(5-6):1

Abstract:

MaLAM is making a formal complaint to the Australian Pharmaceutical Manufacturers Association aobut three separate issues: the use of loose leaf inserts in medical journals since they are prohibited by the revisions to the APMA’s Code of Conduct; Glaxo Wellcome’s marketing of Lamictal (lamotrigine) which omitted safety information; and Hoffman LaRoche’s promotion of Aurorix (moclobemide) in the a mass market magazine.

Keywords:
*analysis/Australia/developed countries/ Australian Pharmaceutical Manufacturers Association/ Code of Conduct (Aus)/ direct-to-consumer advertising/ DTCA/ safety & risk information/ quality of information/Glaxo-Wellcome/Hoffman LaRoche/Lamictal/lamotrigine/Aurorix/moclobemide/MaLAM/Medical Lobby for Appropriate Marketing/EVALUATION OF PROMOTION: DIRECT-TO-CONSUMER ADVERTISING/EVALUATION OF PROMOTION: DRUG SAFETY/EVALUATION OF PROMOTION: PROMOTIONAL BROCHURES/PROMOTION AND HEALTH NEEDS: PROMOTION IN DEVELOPED COUNTRIES/REGULATION, CODES, GUIDELINES: INDUSTRY SELF-REGULATION